Today’s Phase II single-dose (Part A) data on the metered dose inhaler (MDI) formulation of ensifentrine in COPD patients are strong, demonstrating a statistically significant and clinically meaningful, dose-response improvement in lung function vs. placebo. This improvement was statistically significant in all doses vs. placebo, except at the lowest strength. Furthermore, this lung function improvement showed statistically significant dose-response durability over 4 hours and 12 hours.
31 Mar 2020
Strong MDI data highlights triple modality of ensifentrine
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong MDI data highlights triple modality of ensifentrine
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
31 Mar 2020 -
Author:
Edward Thomason -
Pages:
4
Today’s Phase II single-dose (Part A) data on the metered dose inhaler (MDI) formulation of ensifentrine in COPD patients are strong, demonstrating a statistically significant and clinically meaningful, dose-response improvement in lung function vs. placebo. This improvement was statistically significant in all doses vs. placebo, except at the lowest strength. Furthermore, this lung function improvement showed statistically significant dose-response durability over 4 hours and 12 hours.